/
CMPS
$15.07+$0.25 (+1.69%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.0B
135M shares
52-week range
$2.68 – $15.40
97% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
ADRC
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-23.08
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $63.0K | $112.9K | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $0 | −$63.0K | −$112.9K | $0 | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $8.9M | $12.6M | $23.4M | $44.0M | $65.1M | $87.5M | $119.0M | $118.4M |
| Operating income | −$12.5M | −$21.2M | −$51.8M | −$83.2M | −$110.4M | −$136.9M | −$178.2M | −$179.0M |
| EBITDA | −$10.5M | −$22.3M | −$64.9M | −$71.4M | −$90.8M | −$115.2M | −$148.8M | −$285.6M |
| Net income | −$13.2M | −$19.6M | −$60.8M | −$71.7M | −$91.5M | −$118.5M | −$155.1M | −$287.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -2.35 | -0.90 | -1.68 | -1.79 | -2.16 | -2.32 | -2.30 | -3.08 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2M | $-0.73 | $-0.91–$-0.43 | 4 |
| 2027 | $66M | $-1.39 | $-2.75–$-0.78 | 4 |
| 2028 | $231M | $-0.25 | $-0.54–$-0.07 | 3 |
| 2029 | $496M | $0.59 | $0.16–$1.27 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$1.38
Price
$15.07
Implied downside
-91%
Peer comparison
COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
compasspathways.com- Employees
- 156
- IPO / List date
- Sep 18, 2020
- HQ
- CHESIRE, X0
Held by traders on TradeandTell
No one on the platform currently holds CMPS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 865,354 | $4.8M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CMPS yet.
